Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 8/2003

01-08-2003 | Brief Report

Characterisation of Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Teicoplanin in Eastern France

Authors: X. Bertrand, D. Hocquet, M. Thouverez, P. Plésiat, D. Talon

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 8/2003

Login to get access

Excerpt

Vancomycin and teicoplanin are very important agents for the treatment of infections caused by multidrug-resistant gram-positive bacteria. However, since 1997, numerous authors worldwide have reported the emergence of methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides [1, 2, 3, 4]. The recent description of two fully vancomycin-resistant strains has underscored the threat caused by these emerging pathogens [5, 6]. In Europe, particularly in France, most glycopeptide-intermediate Staphylococcus aureus (GISA) strains display decreased susceptibility to teicoplanin but not to vancomycin [4, 7, 8, 9]. …
Literature
1.
Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, Fukuchi Y, Kobayashi I (1997) Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogenously resistant to vancomycin. Lancet 350:1670–1673PubMed
2.
Ploy MC, Grelaud C, Martin C, Lumley L de, Denis F (1998) First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 351:1212
3.
Aucken HM, Ganner M, Murchan S, Copkson BD, Johnson AP (2002) A new UK strain of epidemic methicillin-resistant Staphylococcus aureus (EMRSA-17) resistant to multiple antibiotics. J Antimicrob Chemother 50:171–175CrossRefPubMed
4.
Guérin F, Buu-Hoi A, Mainardi JL, Kac G, Colardelle N, Vaupré S, Guttman L, Podglajen I (2000) Outbreak of methicillin-resistant Staphylococcus aureus with decreased susceptibility to glycopeptides in a Parisian hospital. J Clin Microbiol 38:2985–2988PubMed
5.
Centers for Disease Control and Prevention (2002) Staphylococcus aureus resistant to vancomycin—United States, 2002. MMWR 51:565–567PubMed
6.
Centers for Disease Control and Prevention (2002) Staphylococcus aureus resistant to vancomycin—Pennsylvania, 2002. MMWR 51:902PubMed
7.
Hassan IA, Chadwick PR, Johnson AP (2001) Clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to teicoplanin in Northwest England. J Antimicrob Chemother 48:454–455CrossRefPubMed
8.
Elsaghier AA, Aucken HM, Hamilton-Miller J, Shaw S, Kibbler CC (2002) Resistance to teicoplanin developing during treatment of methicillin-resistant Staphylococcus aureus infection. J Antimicrob Chemother 49:423–424CrossRefPubMed
9.
Lecaillon E, Gueudet P, Wooton M, Walsh TR, Macgowan AP, Jones ME (2002) Endemic hetero-resistant glycopeptide intermediate Staphylococcus aureus (hGISA) comprising unrelated clonal types and not associated with vancomycin therapy. Pathol Biol 50:525–529CrossRefPubMed
10.
Bertrand X, Thouverez M, Talon D (2000) Antibiotic susceptibility and genotypic characterization of methicillin-resistant Staphylococcus aureus strains in eastern France. J Hosp Infect 46:280–287CrossRefPubMed
11.
Andersson DI, Levin BR (1999) The biological cost of antibiotic resistance. Curr Opin Microbiol 2:489–493CrossRefPubMed
Metadata
Title
Characterisation of Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Teicoplanin in Eastern France
Authors
X. Bertrand
D. Hocquet
M. Thouverez
P. Plésiat
D. Talon
Publication date
01-08-2003
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 8/2003
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-003-0966-7

Other articles of this Issue 8/2003

European Journal of Clinical Microbiology & Infectious Diseases 8/2003 Go to the issue

Concise Article

Evaluation of the Merlin, Micronaut System for Automated Antimicrobial Susceptibility Testing of Pseudomonas aeruginosa and Burkholderia Species Isolated from Cystic Fibrosis Patients

Article

Significance of Aspergillus fumigatus Isolation from Respiratory Specimens of Nongranulocytopenic Patients

Concise Article

Incidence and Risk Factors for Nosocomial Infections Caused by Fluoroquinolone-Resistant Escherichia coli

Announcements

August 2003

Concise Article

Staphylococcus lugdunensis Endocarditis—The Hidden Peril of Coagulase-Negative Staphylococcus in Blood Cultures

Brief Report

Cerebral Abscess due to Gemella morbillorum
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits